Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Y.Y. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Shin, S.-J. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Yang, H.-K. | - |
dc.contributor.author | Kim, W.H. | - |
dc.contributor.author | Kim, Y.-W. | - |
dc.contributor.author | Kook, M.-C. | - |
dc.contributor.author | Park, Y.K. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Lee, H.S. | - |
dc.contributor.author | Lee, K.H. | - |
dc.contributor.author | Gu, M.J. | - |
dc.contributor.author | Choi, S.H. | - |
dc.contributor.author | Hong, S. | - |
dc.contributor.author | Kim, J.W. | - |
dc.contributor.author | Hyung, W.J. | - |
dc.contributor.author | Noh, S.H. | - |
dc.contributor.author | Cheong, J.-H. | - |
dc.date.available | 2019-08-30T03:01:26Z | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 1528-1140 | - |
dc.identifier.issn | 1528-1140 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/36494 | - |
dc.description.abstract | OBJECTIVE: We investigated microsatellite instability (MSI) status and programed cell death ligand 1 (PD-L1) expression as predictors of prognosis and responsiveness to chemotherapy for stage II/III gastric cancer. BACKGROUND: The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated. METHODS: Tumor specimens and clinical information were collected from patients enrolled in the CLASSIC trial-a randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy. Five quasi-monomorphic mononucleotide markers were used to assess tumor MSI status. PD-L1 expressions of tumor and stromal immune cells were evaluated using immunohistochemistry. RESULTS: Of 592 patients, 40 (6.8%) had MSI-high (MSI-H) tumors. Among 582 patients available for immunohistochemistry evaluation, PD-L1 was positive in tumor cells (tPD-L1) of 16 patients (2.7%) and stromal immune cells (sPD-L1) of 165 patients (28.4%). Multivariable analysis of disease-free survival (DFS) showed that MSI-H and sPD-L1-positivity were independent prognostic factors [hazard ratio 0.301 (0.123-0.736), 0.714 (0.514-0.991); P = 0.008, 0.044), as were receiving chemotherapy, age, tumor grade, and TNM stage. Although adjuvant chemotherapy improved DFS in the microsatellite-stable (MSS) group (5-year DFS: 66.8% vs 54.1%; P = 0.002); no benefit was observed in the MSI-H group (5-year DFS: 83.9% vs 85.7%; P = 0.931). In the MSS group, sPD-L1-negative patients, but not sPD-L1-positive patients, had significant survival benefit from adjuvant chemotherapy compared with surgery only (5-year DFS: 66.1% vs 50.7%; P = 0.001). CONCLUSION: MSI status and PD-L1 expression are clinically actionable biomarkers for stratifying patients and predicting benefit from adjuvant chemotherapy after D2 gastrectomy for stage II/III gastric cancer. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | NLM (Medline) | - |
dc.title | Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/SLA.0000000000002803 | - |
dc.identifier.bibliographicCitation | Annals of surgery, v.270, no.2, pp 309 - 316 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000480739600070 | - |
dc.identifier.scopusid | 2-s2.0-85069851897 | - |
dc.citation.endPage | 316 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 309 | - |
dc.citation.title | Annals of surgery | - |
dc.citation.volume | 270 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | biomarker | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | microsatellite instability | - |
dc.subject.keywordAuthor | programmed cell death ligand 1 | - |
dc.subject.keywordPlus | III COLON-CANCER | - |
dc.subject.keywordPlus | MISMATCH REPAIR | - |
dc.subject.keywordPlus | ADJUVANT CAPECITABINE | - |
dc.subject.keywordPlus | ANTI-PD-L1 ANTIBODY | - |
dc.subject.keywordPlus | PROTEIN EXPRESSION | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTOR | - |
dc.subject.keywordPlus | PD-L1 EXPRESSION | - |
dc.subject.keywordPlus | BRAF MUTATION | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.